Sarepta Therapeutics (SRPT) Tops Q4 EPS by 29c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments
February 26, 2020 4:05 PM ESTCAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three and twelve months ended December 31, 2019.
The Sarepta team made great progress in service of our vision to be one of the worlds most meaningful leaders in precision genetic medicine in 2019, and profoundly so in the fourth quarter, stated Doug Ingram, Sareptas President and Chief Executive Officer. We continued to serve the Duchenne community with EXONDYS 51, achieving revenue of $100 million in the fourth... More
